The molecular mechanisms and therapeutic potential of microRNA-7 in cancer

被引:54
作者
Gu, Dian-Na [1 ]
Huang, Qian [2 ,3 ]
Tian, Ling [1 ,2 ,3 ]
机构
[1] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 1, Expt Res Ctr, Shanghai 201620, Peoples R China
[2] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 1, Ctr Canc, Shanghai 201620, Peoples R China
[3] Shanghai Jiao Tong Univ Sch Med, Shanghai Peoples Hosp 1, Shanghai Key Lab Pancreat Dis, Shanghai 201620, Peoples R China
基金
国家高技术研究发展计划(863计划); 美国国家科学基金会;
关键词
cancer cell signaling; microRNA; microRNA-7; microRNA-based therapeutics; post-transcriptional regulation; GROWTH-FACTOR RECEPTOR; PROTEASOME ACTIVATOR PA28-GAMMA; FOCAL ADHESION KINASE; YIN YANG 1; BREAST-CANCER; CELL-CYCLE; STRUCTURAL BASIS; XIAP EXPRESSION; UP-REGULATION; REG-GAMMA;
D O I
10.1517/14728222.2014.988708
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Introduction: Increasing evidence supports that microRNAs (miRNAs) play crucial roles in cancer through post-transcriptional gene silencing of their target genes, therefore, more and more effort has been devoted to develop miRNA-targeting therapeutics in cancer. MicroRNA-7 (miR-7) has been characterized as a potential tumor suppressor and regulates diverse fundamental biological processes of cancer cells including initiation, proliferation, migration, invasion, survival and death by targeting a number of oncogenic signaling pathways. Areas covered: This review examines evidence of the biological responses of miR-7 in cancer, with an emphasis on its regulation of the vital oncogenic signaling pathways. It also discusses the rationale, strategies and challenges of miR-7 as a potential therapeutic target for cancer. Expert opinion: With the increasing understanding of molecular mechanisms of miR-7-mediated regulatory networks and the advancement of miRNA-based therapeutics, targeting miR-7 may be a potential and promising strategy for cancer therapy.
引用
收藏
页码:415 / 426
页数:12
相关论文
共 101 条
[1]
Ahmed FE, 2013, CANCER GENOM PROTEOM, V10, P93
[2]
The IGF system [J].
Annunziata, Marta ;
Granata, Riccarda ;
Ghigo, Ezio .
ACTA DIABETOLOGICA, 2011, 48 (01) :1-9
[3]
[Anonymous], GASTROENTEROLOGY
[4]
A Rac-Pak signaling pathway is essential for ErbB2-mediated transformation of human breast epithelial cancer cells [J].
Arias-Romero, L. E. ;
Villamar-Cruz, O. ;
Pacheco, A. ;
Kosoff, R. ;
Huang, M. ;
Muthuswamy, S. K. ;
Chernoff, J. .
ONCOGENE, 2010, 29 (43) :5839-5849
[5]
INTERFERING NANOPARTICLES FOR SILENCING MICRORNAS [J].
Baigude, Huricha ;
Rana, Tariq M. .
NANOMEDICINE: INFECTIOUS DISEASES, IMMUNOTHERAPY, DIAGNOSTICS, ANTIFIBROTICS, TOXICOLOGY AND GENE MEDICINE, 2012, 509 :339-353
[6]
Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells [J].
Begon, DY ;
Delacroix, L ;
Vernimmen, D ;
Jackers, P ;
Winkler, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (26) :24428-24434
[7]
Homeobox D10 induces phenotypic reversion of breast tumor cells in a three-dimensional culture model [J].
Carrio, M ;
Arderiu, G ;
Myers, C ;
Boudreau, NJ .
CANCER RESEARCH, 2005, 65 (16) :7177-7185
[8]
Structural basis of caspase-7 inhibition by XIAP [J].
Chai, JJ ;
Shiozaki, E ;
Srinivasula, SM ;
Wu, Q ;
Dataa, P ;
Alnemri, ES ;
Shi, YG .
CELL, 2001, 104 (05) :769-780
[9]
Ubiquitin-independent degradation of cell-cycle inhibitors by the REGγ proteasome [J].
Chen, Xueyan ;
Barton, Lance F. ;
Chi, Yong ;
Clurman, Bruce E. ;
Roberts, James M. .
MOLECULAR CELL, 2007, 26 (06) :843-852
[10]
Chen YJ, 2013, EVID BASED COMPL ALT, V2013